COVID-19 Drugs: University Of Cincinnati Study Warns Against Use Of U.S. FDA Approved Remdesivir Due to Drug Interactions And Increased Toxicity
: A new study by researchers from the University Of Cincinnati warns against the use of the overpriced U.S. FDA approved remdesivir drug and in situations when it is being still used, extra caution and monitoring need to be observed as the drug exhibits drug interactions with numerous drugs and increases toxicity.
The study findings were published in the peer reviewed journal: Fundamental and Clinical Pharmacology. https://onlinelibrary.wiley.com/doi/10.1111/fcp.12643
Remdesivir was approved by the U.S. FDA to treat COVID‐19 although new studies now show that it has no efficacy to treat COVID-19. https://www.thailandmedical.news/news/latest-who-s-solidarity-drug-trial-shows-that-remdesivir-is-not-the-least-effective-in-treating-covid-19
Several safety concerns in many cases have been raised about its use. https://www.thailandmedical.news/news/covid-19-scams-who-issues-warning-against-use-of-remdesivir-for-covid-19--countries-should-beware-of-any-therapeutics-approved-in-the-usa
This study reports that remdesivir at nanomolar concentrations inhibits carboxylesterase‐2 (CES2) through covalent modifications. CES2 is a major drug‐metabolizing enzyme. The combination of high potency with irreversible inhibition concludes that cautions must be exercised when remdesivir is used along with drugs hydrolyzed by CES2.
The world is too engrossed on vaccines to stop the spread of coronavirus, but therapeutics are still necessary to treat hospitalized patients. One of these treatments, remdesivir, is the first and only antiviral agent of its kind that the U.S. Food and Drug Administration (FDA) has approved so far for COVID-19.
Scientists the University of Cincinnati, however, contend that this antiviral drug is being used too indiscriminately when treating patients hospitalized with the virus.
The U.S. FDA under the Trump administration approved remdesivir, marketed as Veklury, for emergency use authorization in May 2020 to treat COVID-19 and granted full approval for treatment in October 2020.
However the World Health Organization came out in November 2020 with a conditional recommendation advising against its use entirely citing: "More research is needed, especially to provide higher certainty of evidence for specific groups of patients."
In this news study by University of Cincinnati, the lead author Professor Dr Bingfang Yan, a pharmaceutical scientist, and his graduate students Dr Yue Shen and Dr William Eades, found that the drug permanently stops the activity of an enzyme called CES-2, which is found in the intestine, liver and kidney and is needed for the breakdown of many medications.
Dr Yan, a professor at the James L. Winkle College of Pharmacy at Unoversity of Cincinnati told Thailand Medical News, "This enzyme normally breaks down and activates medicines in certain antivirals or inactivates other medicines such in certain anticoagulants. On the other hand this breakdown increases the toxicity of many more medications such as with heart medicines and anticancer drugs
Typically an antiviral is a drug against viruses and an anticoagulant is a drug that hinders the clotting of blood.
What further complicates the issue, Dr Yan says, is that when delivered through an IV, remdesivir does not treat the virus unless the body has additional specific enzymes, which are not found in all patients. It can also cause other antiviral drugs, such as those used for HIV/AIDS and hepatitis C, to not work properly.
The drug remdesivir is only administered through the veins in a hospital setting, with the FDA typically recommending a dose of once a day, for approximately 10 days, and "intravenous injection of remdesivir can cause safety concerns because of high initial concentrations of the drug in the system," says Dr Yan, noting, "If physicians use it, they have to use it with caution."
Dr Yan warned, "Clearly, the treatment should be used for the right patients and in the proper dosages with care when used in combination with other medications."
Remdesivir is one of the most overpriced drugs that the U.S. FDA under the Trump Administration is promoting, priced at more than US$ 3,100 dose.
There is currently an oversupply of the drug in India with very little takers that has led to the prices falling below US$7 per dose in India!
Thailand Medical News has been warning about the many COVID-19 scams perpetrated by governments, politicians, billionaire businessmen, pharmaceutical companies, and huge corporations in the United States and the United Kingdom. However with big monies involved, some of these entities have bought American social media platforms and search engines to try to hide some of our exposures of these scams by lowering our news feed and also our SEO rankings so that no one could easily find all these articles, along with even death threats to us and even physical abuse.
Please help share this article and let more people know about the existence of our site and also please help to sustain this site and all the research initiatives we propel and also conduct ourselves by making a donation. https://www.thailandmedical.news/p/sponsorship
For more on COVID-19 Drugs
, keep on logging to Thailand Medical News.